Data / Drug companies / Lipoglycopeptide Antibacterial
Lipoglycopeptide Antibacterial drugs: 5 drugs from 9 companies in the FDA NDC directory
Lipoglycopeptide Antibacterial is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 10 products in this class from 9 companies, covering 5 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on July 27, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 9Companies
- 10Products
- 5Drugs by generic name
Drugs in the Lipoglycopeptide Antibacterial class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Dalbavancin | 5 | 5 |
| Dalbavancin hydrochloride | 2 | 2 |
| Oritavancin | 1 | 1 |
| Oritavancin diphosphate | 1 | 1 |
| Telavancin hydrochloride | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Melinta Therapeutics, LLC | 2 | injection, powder, lyophilized, for solution | New drug applications (NDA) | March 23, 2021 |
| Allergan, Inc. | 1 | injection, powder, for solution | New drug applications (NDA) | May 23, 2014 |
| Be Pharmaceuticals Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 12, 2026 |
| Cumberland Pharmaceuticals Inc. | 1 | injection, powder, lyophilized, for solution | New drug applications (NDA) | January 1, 2021 |
| Fresenius Kabi USA, LLC | 1 | injection, powder, for solution | Generic drugs (ANDA) | November 10, 2025 |
| Long Grove Pharmaceuticals, LLC | 1 | injection, powder, for solution | Generic drugs (ANDA) | March 3, 2026 |
| Meitheal Pharmaceuticals Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 26, 2025 |
| Somerset Therapeutics, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 27, 2026 |
| Teva Pharmaceuticals, Inc. | 1 | injection, powder, for solution | Generic drugs (ANDA) | October 29, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 6 | 60% |
| Injection, powder, for solution | 4 | 40% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.